Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene that abolish
the expression of dystrophin protein. Dogs with the genetic homologue, golden retriever …

Fibrosis is a prominent pathological feature of skeletal muscle in Duchenne muscular
dystrophy (DMD). The commonly used disease mouse model, mdx 5cv, displays progressive …

Deficiency in the membrane cytoskeletal protein dystrophin is the underlying cause of the
progressive muscle wasting disease named Duchenne muscular dystrophy. In order to …

Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …

Patients with neuromuscular disorders suffer from a lack of treatment options for skeletal
muscle weakness and disease comorbidities. Here, we introduce as a potential therapeutic …

Motor neuron (MN) diseases are progressive disorders resulting from degeneration of
neuromuscular junctions (NMJs), which form the connection between MNs and muscle …

Eteplirsen is FDA-approved for the treatment of Duchenne muscular dystrophy (DMD) in
exon 51 skip-amenable patients. Previous studies in boys> 4 years of age indicate …

Muscle atrophy is an active process controlled by specific transcriptional programs, in which
muscle mass is lost by increased protein degradation and/or decreased protein synthesis …

Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy and is
caused by mutations in the dystrophin gene. Dystrophin deficiency is associated with …

Background The lack of dystrophin expression in Duchenne muscular dystrophy (DMD)
induces muscle fibre and replacement by fibro‐adipose tissue. Although the role of some …